Glycosylated hemoglobin measurement (HbAc) < .%
Within less than or equal to  days prior to registration: Glycosylated hemoglobin (HbAc) < .%
Glycosylated hemoglobin (HbAC) >= .%
Glycated hemoglobin (HbAc) < .%, within  days of registration
Glycosylated hemoglobin (HbAc) =< .%
Glycosylated hemoglobin (HbAc) < .%.
Have a baseline glycated hemoglobin (HbAc) ? .
Glycosylated hemoglobin (HbAc) =< . %
Patients with diabetes are allowed and may be on antidiabetic treatment other than metformin; the diabetes must be under control within normal range (glycosylated hemoglobin measurement [HbAC] =< .%)
Glycosylated hemoglobin (HbAc) =< .%
Metabolic: glycosylated hemoglobin (HbAc) < .%
Glycosylated hemoglobin (HbAc) > .% or fasting plasma glucose >  mg/dL at screening
HbAc > .% at Screening
Glycosylated hemoglobin (HbAc) < .%
Metabolic - Glycated hemoglobin (HbAc) ? %
Patients with HbAc > .% at Screening
Glycosylated hemoglobin (HbAc) < .%
Glycosylated hemoglobin (HbAc) =<  % (Gedatolisib can cause hyperglycemia)
Patients must have a sodium (Na), potassium (K), chlorine (Cl), calcium (Ca), magnesium (Mg), and glycosylated hemoglobin measurement (HbAc) performed within  days prior to sub-study registration
Patient has uncontrolled diabetes, defined as a fasting serum glucose >  mg/dl or glycosylated hemoglobin (hemoglobin Ac [HbAc]) > % at screening
HbAc of ? % (all subjects will have HbAc test at screening)
Glycosylated hemoglobin (HbAc) >=. percent (%)
History of diabetes requiring treatment, glucose > mg/dL, Glycated hemoglobin (HbAc) ?.%
HbAc > %.
Patients with diabetes or in risk for hyperglycemia should not be excluded from trials with MK-, but the hyperglycemia should be well controlled before the patient enters the trial (glycosylated hemoglobin [Hbac] < .)
HbAc ? %
Glycated hemoglobin (HbAc) =< %
Glycosylated hemoglobin (HbAc) < .%
Glycosylated hemoglobin measurement (HbAc) < .% within  days of enrollment
Fasting blood glucose level >  and glycosylated hemoglobin (HbAc) > %.
Glycated hemoglobin (HbAc) > %
HbAc =< .%